Britain could give regulatory approval to Pfizer-BioNTech's COVID-19 vaccine this week, even before the United States authorises it, the Telegraph news site reported on Sunday.
Citing government sources, it said British regulators were about to start a formal appraisal of the vaccine, made by Pfizer Inc and BioNTech SE, and that the National Health Service had been told to be ready to administer it by December 1.
Also read: Coronavirus | Pfizer ends COVID-19 vaccine trial with 95% efficacy, to seek emergency-use authorisation
The U.S. Food and Drug Administration said on Friday that it would meet on December 10 to discuss whether to authorise the vaccine.
The U.K. Department of Health had no comment on Sunday on when the first vaccinations would be administered.
Also read: Pfizer seeking emergency use of its COVID-19 vaccine in U.S.
A spokesman said the authorisation process by the medical regulator Medicines and Healthcare Products Regulatory Agency (MHRA) is independent of the government and will take as long as they need to review the final data from Pfizer.
“An enormous amount of planning has taken place to ensure our health service stands ready to roll out a COVID-19 vaccine,” the spokesman added.
Also read: Coronavirus | Israel signs deal with Pfizer for potential COVID-19 vaccine
Britain formally asked its medical regulator, the MHRA, last week to assess the suitability of the Pfizer-BioNTech vaccine.
Britain has ordered 40 million doses and expects to have 10 million doses, enough to protect 5 million people, available by the end of the year if regulators approve it.
You have reached your limit for free articles this month.
Subscription Benefits Include
Today's Paper
Find mobile-friendly version of articles from the day's newspaper in one easy-to-read list.
Unlimited Access
Enjoy reading as many articles as you wish without any limitations.
Personalised recommendations
A select list of articles that match your interests and tastes.
Faster pages
Move smoothly between articles as our pages load instantly.
Dashboard
A one-stop-shop for seeing the latest updates, and managing your preferences.
Briefing
We brief you on the latest and most important developments, three times a day.
Support Quality Journalism.
*Our Digital Subscription plans do not currently include the e-paper, crossword and print.
A letter from the Editor
Dear subscriber,
Thank you!
Your support for our journalism is invaluable. It’s a support for truth and fairness in journalism. It has helped us keep apace with events and happenings.
The Hindu has always stood for journalism that is in the public interest. At this difficult time, it becomes even more important that we have access to information that has a bearing on our health and well-being, our lives, and livelihoods. As a subscriber, you are not only a beneficiary of our work but also its enabler.
We also reiterate here the promise that our team of reporters, copy editors, fact-checkers, designers, and photographers will deliver quality journalism that stays away from vested interest and political propaganda.
Suresh Nambath
Please Email the Editor